Alvotech SDB (ALVO-SDB) fair value: what the stock is really worth
As of Oct 5, 2026: fair value of Alvotech SDB SEK 23.39, price SEK 61.00, upside -61.7%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Show more
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Stock analysis
Alvotech SDB (ALVO-SDB) currently trades at kr 61.00, while our model-based Fair Value estimate is kr 23.39, 61.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 36.68 per share, and 0 of the 8 models we run sit above the kr 61.00 price.
Bear case: the Multiples group reads lowest at kr 13.42, and 8 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 16.37 (bear) to kr 30.41 (bull), the price of kr 61.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Alvotech SDB reported revenue of $586M in FY2025 versus $83.0M in FY2022, a compound +91.9%/yr. Reported net income was $27.9M in FY2025.
Key figures
Market cap 21.8B SEK (≈ $2.2B) · P/S ratio 40.0 · Net margin 4.8% · Return on assets (EBIT) −17.1% · Operating margin −11.1% · Revenue (TTM) $495M · Revenue growth (YoY) −38.9% · EPS growth (YoY) −99.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 29% below its 52-week high and 119% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −62%, ALVO-SDB screens richer than that median.
Fair Value models
Bear kr 16.37Fair Value kr 23.39Bull kr 30.41
Price kr 61.00 · Upside -61.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.9%
’22
’23
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 600 stocks
Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside−61.7% · Bottom 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets2.2% · Below median
Net margin (TTM)−36.3% · Bottom 25%
Operating margin (TTM)−11.1% · Bottom 25%
Growth and dividend
Revenue growth−38.9% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alvotech SDB Fair Value". https://www.fairvalue-calculator.com/stock/ALVO-SDB
Frequently asked questions
Is Alvotech SDB (ALVO-SDB) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of kr 23.39 versus a price of kr 61.00, about −62% upside (overvalued).
What is the fair value of ALVO-SDB?
Our model-based fair value for Alvotech SDB is kr 23.39 (as of Oct 2, 2026), built from audited fundamentals. The current price: kr 61.00.
What is the quality score of ALVO-SDB?
Alvotech SDB has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alvotech SDB (ALVO-SDB)?
Our model-based price target is the fair value of kr 23.39 (as of Oct 2, 2026) from 9 valuation models. Cautious scenario kr 16.37, optimistic scenario kr 30.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Alvotech SDB stock forecast for 2026?
Our models put fair value at kr 23.39, about −62% upside versus a price of kr 61.00 (overvalued). Cautious scenario kr 16.37, optimistic scenario kr 30.41. The calculation is refreshed regularly with new filings.
What is the revenue of Alvotech SDB (ALVO-SDB)?
Alvotech SDB reported trailing-twelve-month revenue of about $495M (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Alvotech SDB (ALVO-SDB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alvotech SDB it is kr 23.39 per share (as of Oct 2, 2026), against a price of kr 61.00. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Alvotech SDB stock overvalued or undervalued in 2026?
As of Oct 2, 2026, ALVO-SDB trades above its calculated fair value: price kr 61.00, fair value kr 23.39, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALVO-SDB?
No. The price is what the market pays today (kr 61.00); the fair value is what the company's own numbers justify (kr 23.39). For Alvotech SDB the two are kr 37.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alvotech SDB worth?
The market values Alvotech SDB at about 21.8B SEK (market capitalisation, as of Oct 2, 2026). Per share that is kr 61.00; our models calculate a fair value of kr 23.39 per share.
What do the bullish and bearish scenarios say about ALVO-SDB?
Our models span a range for Alvotech SDB: cautious scenario kr 16.37, base kr 23.39, optimistic kr 30.41 per share (as of Oct 2, 2026, price kr 61.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Alvotech SDB (ALVO-SDB)?
Balance-sheet figures for Alvotech SDB (as of Oct 2, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is ALVO-SDB from its 52-week high?
Alvotech SDB trades at kr 61.00, about 29% below its 52-week high of kr 85.50 and 119% above the low of kr 27.85 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of kr 23.39 is for.
Which stocks are comparable to Alvotech SDB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alvotech SDB stock attractive at the current price?
The data as of Oct 2, 2026: price kr 61.00, calculated fair value kr 23.39 (−62%), Quality Score 22/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALVO-SDB calculated?
We run Alvotech SDB through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 23.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Alvotech SDB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alvotech SDB (ALVO-SDB)?
The closing price on Oct 5, 2026 was kr 61.00. Our model-based fair value is kr 23.39, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alvotech SDB right now?
The price sits above even our optimistic bull case (kr 30.41). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 16.37 to kr 30.41) leaves room in how you read the outcome.
Key figures of Alvotech SDB
How large is the market capitalisation of Alvotech SDB (ALVO-SDB)?
The market capitalisation of Alvotech SDB is 21.8B SEK (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alvotech SDB (ALVO-SDB)?
The price-to-sales ratio of Alvotech SDB is 40.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Alvotech SDB (ALVO-SDB)?
The net margin of Alvotech SDB is 4.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Alvotech SDB (ALVO-SDB)?
On an EBIT basis the return on assets of Alvotech SDB is −17.1% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alvotech SDB (ALVO-SDB)?
The operating margin of Alvotech SDB is −11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alvotech SDB (ALVO-SDB)?
Revenue at Alvotech SDB is growing −38.9% versus a year earlier (3y avg +91.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alvotech SDB (ALVO-SDB)?
Earnings per share at Alvotech SDB are growing −99.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Alvotech SDB (ALVO-SDB) generate?
The free cash flow of Alvotech SDB is −$146M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Alvotech SDB (ALVO-SDB) carry?
The net debt of Alvotech SDB is $1.1B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Alvotech SDB in the live analysis
One click puts Alvotech SDB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
